Keith Katkin

Keith Katkin is a highly accomplished business executive and a graduate of the prestigious University of California, Los Angeles - The Anderson School of Management, where he earned his MBA degree. He also holds a bachelor's degree in Business from Indiana University Bloomington. With a wealth of experience across various industries, he has served in numerous leadership positions throughout his career.

Currently, Keith is an Adviser to the Board of Directors at Urovant Sciences, Inc., a biopharmaceutical company. Previously, he served as the President and CEO of Urovant Sciences, during which time he successfully led the company through a merger with Sumitovant Biopharma, resulting in a $3.3 billion valuation. Prior to Urovant, Keith held executive roles at a number of other pharmaceutical companies, including Avanir Pharmaceuticals where he served as CEO, InterMune where he was Vice President of Marketing, and Peninsula Pharmaceuticals where he was Vice President of Commercial Development.

Keith also has an extensive background serving on the boards of various pharmaceutical companies, including Syndax Pharmaceuticals, Rigel Pharmaceuticals Inc., Otic Pharma Ltd., CoverMyMeds, and Carbylan Therapeutics. He has been recognized for his outstanding leadership skills, and his dedication to improving the lives of patients in need of innovative therapies.

With a rich and accomplished background in Sales, Marketing, Business Development, and Commercial Operations, Keith Katkin is a highly respected and successful business executive in the pharmaceutical industry and beyond.